Previously published real-life experience of CPX-351 in a cohort of 103 French high-risk AML patients could confirm the inferior outcome of those patients harboring TP53 or PTPN11 mutations (Chiche et al. 2021; Walter et al. 2012). This evidence concerns the gene TP53 and acute myeloid leukemia.